AbbVie faced a major challenge as Humira sales plummeted after biosimilars entered the market, dropping from $21 billion annually to $688 million in Q1 2026. However, the company successfully pivoted with strong growth in newer drugs Skyrizi and Rinvoq, generating $4.483 billion and $2.119 billion respectively in Q1 2026. The 2020 Allergan acquisition added valuable products like Botox and Juvederm, boosting revenue to $61.16 billion in 2025. AbbVie raised its 2026 earnings guidance and has delivered a 400% return over 10 years, outperforming the S&P 500. Investors see potential in AbbVie's pipeline and dividend yield, though risks remain from future patent expirations starting in 2028.
BOTOX Cosmetic, under Allergan Aesthetics and AbbVie, announced 250 women entrepreneurs chosen for The Confidence Collective program, offering skill-building, mentorship, and networking. From this group, 20 participants will receive $20,000 grants to...
Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, sho...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eigh...
Following AbbVie's pending acquisition of Apogee Therapeutics, big pharma is actively seeking clinical-stage biotech firms with late-stage data and strategic fit in immunology, obesity, or oncology. Among Nasdaq-listed biotechs, Syndax Pharmaceutical...
